Volitinib is an inhibitor of c-Met. It shows antitumor potential in models of gastric cancer. It is being investigated as a treatment for papillary renal cell carcinoma, where it has demonstrated an acceptable tolerability profile.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.